Lv3
270 积分 2025-04-14 加入
An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIII
9小时前
待确认
The evolving landscape of obesity pharmacotherapy
28天前
已完结
Medical management of inflammatory bowel diseases
3个月前
已完结
An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics
3个月前
已完结
Therapeutically harnessing extracellular vesicles
4个月前
已完结
Pediatric Developmental Drug Toxicity: Description of Juvenile Animal Studies in US FDA Prescribing Information and Assessing the Need for New Approach Methodologies
5个月前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
5个月前
已完结
A CDER Perspective: Landscape of New Approach Methodologies (NAMs) submitted in Drug Development Programs
5个月前
已完结
Impurity Qualification Thresholds: An IQ Survey on Emerging Industry Experience with Health Authority Feedback
6个月前
已完结
Application of new approach methodologies for nonclinical safety assessment of drug candidates
6个月前
已完结
皖公网安备34019202002308
